Abstract
A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient’s vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steg, R., Kessinger, A. & Wszolek, Z. Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation. Bone Marrow Transplant 23, 959–962 (1999). https://doi.org/10.1038/sj.bmt.1701732
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701732
Keywords
This article is cited by
-
Benign cerebral angiopathy; postpartum cerebral angiopathy: Characteristics and treatment
Current Treatment Options in Cardiovascular Medicine (2006)
-
Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients
Bone Marrow Transplantation (2001)
-
Cyclosporin A-related cerebral vasculopathy
Bone Marrow Transplantation (2000)
-
FK506-induced intractable leukoencephalopathy following allogeneic bone marrow transplantation
Bone Marrow Transplantation (2000)